[O6] Oral Session 6　Lung Cancer / Thoracic Cancer 1（Molecularly-targeted therapy EGFR, ALK）
【E】

[O6-5] Brigatinib (BRG) Versus Crizotinib (CRZ) in Patients With ALK TKI-Naive ALK-Positive NSCLC: Final Results From ALTA-1L

^○Hye Ryun Kim¹, Sanjay Popat², Myung-Ju Ahn³, James Ch Yang⁴, Ji-Youn Han⁵, Maximilian J Hochmair⁶, Ki Hyeong Lee⁷, Angelo Delmonte⁸, Maria Rosario Garcia Campelo⁹, Dong-Wan Kim¹⁰, Frank Griesinger¹¹, Enriqueta Felip¹², Raffaele Califano¹³, Alexander I Spira¹⁴, Scott N Gettinger¹⁵, Marcello Tiseo¹⁶, Huamao M Lin¹⁷, Yuyin Liu¹⁷, Florin Vranceanu¹⁷, D Ross Camidge¹⁸ (1.Yonsei Cancer Center, Yonsei University College of Medicine, 2.Royal Marsden Hospital, London, England, United Kingdom, 3.Samsung Medical Center, Seoul, South Korea, 4.National Taiwan University Cancer Center, Taipei, Taiwan, 5.National Cancer Center, Goyang, South Korea, 6.Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna, Austri, 7.Chungbuk National University Hospital, Cheongju, South Korea, 8.Scientific Institute of Romagna for the Study and Treatment of Cancer, Meldola, Italy, 9.University Hospital A Coruña, CHUAC, A Coruña, Spain, 10.Seoul National University Hospital, Seoul, South Korea, 11.Pius-Hospital Oldenburg, University of Oldenburg, Germany, 12.Vall d'Hebron University Hospital, Barcelona, Spain, 13.The Christie NHS Foundation Trust, Manchester, England, United Kingdom, 14.Virginia Cancer Specialists and US Oncology Research, The Woodlands, TX, USA, 15.Yale Cancer Center, New Haven, CT, USA, 16.University Hospital of Parma, Parma, Italy, 17.Takeda Development Center Americas, Inc., Lexington, MA, USA, 18.University of Colorado Cancer Center, Aurora, CO, USA)